Risperidone for Self-Injurious Behaviors and OCD
Risperidone is FDA-approved and effective for self-injurious behaviors in autistic disorder but is NOT a first-line treatment for OCD—it should only be used as augmentation to SSRIs in treatment-resistant OCD cases.
Self-Injurious Behaviors
FDA-Approved Indication
Risperidone is specifically FDA-approved for treating irritability associated with autistic disorder in children and adolescents (ages 5-17 years), which includes aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods 1.
Evidence for Efficacy
- In autistic disorder: Two 8-week placebo-controlled trials demonstrated significant improvement in self-injurious behaviors, with mean doses of 1.4-1.9 mg/day (0.05-0.06 mg/kg/day) 1
- In intellectual disabilities: A 2023 meta-analysis showed a small effect size (SMD -0.238) for self-injury reduction post-intervention, with antipsychotics (including risperidone) demonstrating larger effects than other medications 2
- Real-world evidence: Case series in adults with moderate to profound mental retardation showed significant reduction in aggression and self-injurious behavior, though sedation and restlessness were common side effects 3
Dosing Approach
Start at 0.25 mg/day (weight <20 kg) or 0.5 mg/day (weight ≥20 kg), titrating to clinical response. Typical effective doses range from 0.5-3.5 mg/day based on weight and response 1.
Obsessive-Compulsive Disorder
NOT First-Line Treatment
SSRIs are the first-line pharmacological treatment for OCD, not risperidone 4. CBT with exposure and response prevention (ERP) and SSRIs have superior evidence, with number needed to treat of 3 for CBT and 5 for SSRIs 4.
Role as Augmentation Only
Risperidone should be considered only after SSRI failure (inadequate response after 8-12 weeks at maximum tolerated doses) 4.
Evidence for Augmentation:
- Mixed efficacy: One double-blind RCT showed 40% response rate with risperidone augmentation versus 0% with placebo in treatment-resistant OCD 5
- Real-world data: In a large Indian OCD clinic database (n=92), only 24% achieved ≥25% reduction in Yale-Brown Obsessive-Compulsive Scale scores, and only 25% continued risperidone long-term due to ineffectiveness or intolerability 6
- Comparative effectiveness: Risperidone may be more effective than aripiprazole for augmentation (72% vs 50% response rate), particularly for obsessions 7
- Important caveat: One trial found CBT augmentation superior to risperidone augmentation of SSRIs 4
When to Consider Risperidone in OCD:
- After failure of at least two adequate SSRI trials (12 weeks each at maximum tolerated doses)
- When CBT is unavailable or not tolerated
- Particularly if comorbid tics or Tourette syndrome present 8
- Better insight at baseline predicts better response 5
Dosing for OCD Augmentation:
Start 0.5 mg/day, titrate to 0.5-3.0 mg/day based on response and tolerability 5. Typical effective dose is 3 mg/day 7.
Critical Safety Considerations
Metabolic and Movement Disorders
- Weight gain: Mean gain of 2 kg in 3-8 weeks in pediatric trials; 5.5 kg at 24 weeks and 8 kg at 48 weeks in longer-term studies 1
- Tardive dyskinesia: 0.1% incidence in pediatric trials, though reversible upon discontinuation 1
- Somnolence: Most common adverse effect, particularly in first two weeks, with median duration of 16 days 1
Monitoring Requirements
- Weight and metabolic parameters (glucose, lipids) at baseline and regularly during treatment
- Movement disorder assessment at each visit
- Risk-benefit reassessment ongoing, particularly given modest effect sizes in OCD
Clinical Algorithm
For Self-Injurious Behaviors (in autism/intellectual disability):
- Confirm diagnosis and rule out medical causes of behavior
- Start risperidone 0.25-0.5 mg/day based on weight
- Titrate every 5-7 days to clinical response (target 0.05-0.06 mg/kg/day)
- Monitor weight, sedation, and movement disorders closely
For OCD:
- First-line: SSRI monotherapy (12 weeks at maximum tolerated dose) OR CBT with ERP
- Second-line: Switch to different SSRI or add CBT if not already tried
- Third-line: Consider risperidone augmentation 0.5-3 mg/day ONLY if:
- Failed ≥2 adequate SSRI trials
- CBT unavailable/not tolerated
- Patient has good insight (predicts better response)
- Reassess after 8 weeks; discontinue if <25% symptom reduction
- Monitor metabolic parameters and movement disorders throughout treatment
The evidence clearly supports risperidone for self-injurious behaviors in autism but relegates it to a third-line augmentation strategy in OCD with modest efficacy and significant side effect burden 2, 4, 8.